A patient acuity model drove efficient and safe staffing through data from a natural language processing model informed by ...

The FDA approved the combination of durvalumab (Imfinzi) plus FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and ...

The FDA has granted accelerated approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced or metastatic, nonsquamous non–small cell lung cancer (NS-NSCLC) with HER2 ...

With evolving standards for handling hazardous drugs, nurses must comply with safety and handling guidelines.

Coiro, an advanced practice nurse practitioner at the John Theurer Cancer Center at Hackensack University Medical Center Stem ...

The most powerful thing we offer is not a medication or a skill: it’s presence. Presence steadies a hand during uncertainty ...

Kristin Daly, MSN, ANP-BC, AOCNP, shares advice for preparing patients for possible adverse effects outside of clinic hours.

Standard treatments recommended by NCCN Guidelines for this setting include fruquintinib (Fruzaqla), regorafenib (Stivarga), ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

The multi-day nature of standard chemotherapy regimens used in extensive-stage small cell lung cancer (ES-SCLC) creates ...

Kennon McCollum, DNP, explains how multiday ES-SCLC chemotherapy regimens heighten myelosuppression risk and drive dose delays.

Luspatercept-aamt (Reblozyl) is among the National Comprehensive Cancer Network (NCCN) guideline recommendations for low-risk ...